BM-520, an original TXA2 modulator, inhibits the action of thromboxane A2 and 8-iso-prostaglandin F2α in vitro and in vivo on human and rodent platelets, and aortic vascular smooth muscles from rodents

Prostaglandins and Other Lipid Mediators

Volumn 84, Issue 1-2, 2007, Pages 14-23

  Rolin, S ^a   Hanson, J ^b   Vastersaegher, C ^a   Cherdon, C ^b   Pratico, D ^c   Masereel, B ^a   Dogne, J M ^a  

^a UNIVERSITY OF NAMUR   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antiplatelet agent; Isoprostanes; Thromboxane A2

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; 8 ISOPROSTAGLANDIN F2 ALPHA; ARACHIDONIC ACID; BM 520; BM 573; N TERT BUTYL N' [2 (3' METHYLPHENYLAMINO) 5 NITROBENZENESULFONYL]UREA; SULOTROBAN; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; TORASEMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; AORTA MEDIA; ARTICLE; ATHEROSCLEROSIS; BINDING AFFINITY; CONTROLLED STUDY; DRUG BINDING; DRUG EFFECT; DRUG STRUCTURE; GUINEA PIG; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; RAT; RODENT; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; VASCULAR SMOOTH MUSCLE;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ANIMALS; AORTA; BLOOD PLATELETS; DINOPROST; DIPHENYLAMINE; GUINEA PIGS; HUMANS; HYDRAZINES; MALE; MODELS, CHEMICAL; MUSCLE, SMOOTH, VASCULAR; RATS; RATS, WISTAR; SULFONYLUREA COMPOUNDS; THROMBOXANE A2;

EID: 34447530704     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2007.03.002     Document Type: Article

References (43)

1. Wang L.H., and Kulmacz R.J. Thromboxane synthase: structure and function of protein and gene. Prostaglandins Other Lipid Mediat 68-69 (2002) 409
2. Hirata M., Hayashi Y., Ushikubi F., et al. Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature 349 (1991) 617
3. Huang J.S., Ramamurthy S.K., Lin X., and Le Breton G.C. Cell signalling through thromboxane A2 receptors. Cell Signal 16 (2004) 521
4. Moncada S., and Vane J.R. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev 30 (1978) 293
5. Gurbel P.A., Murugesan S.R., Lowry D.R., and Serebruany V.L. Plasma thromboxane and prostacyclin are linear related and increased in patients presenting with acute myocardial infarction. Prostaglandins Leukot Essent Fatty Acids 61 (1999) 7
6. Wenzel S.E. Arachidonic acid metabolites: mediators of inflammation in asthma. Pharmacotherapy 17 (1997) 3S
7. Dogne J.M., de Leval X., Delarge J., David J.L., and Masereel B. New trends in thromboxane and prostacyclin modulators. Curr Med Chem 7 (2000) 609
8. Dogne J.M., Hanson J., de Leval X., et al. Pharmacological characterization of N-tert-butyl-N′-[2-(4′-methylphenylamino)-5-nitrobenzenesulfonyl]urea (BM-573), a novel thromboxane A2 receptor antagonist and thromboxane synthase inhibitor in a rat model of arterial thrombosis and its effects on bleeding time. J Pharmacol Exp Ther 309 (2004) 498
9. Dogne J.M., Hanson J., and Pratico D. Thromboxane, prostacyclin and isoprostanes: therapeutic targets in atherogenesis. Trends Pharmacol Sci 26 (2005) 639
10. Dogne J.M., Hanson J., de Leval X., et al. From the design to the clinical application of thromboxane modulators. Curr Pharm Des 12 (2006) 903
11. Morrow J.D., Minton T.A., Mukundan C.R., et al. Free radical-induced generation of isoprostanes in vivo. Evidence for the formation of D-ring and E-ring isoprostanes. J Biol Chem 269 (1994) 4317
12. Lawson J.A., Rokach J., and FitzGerald G.A. Isoprostanes: formation, analysis and use as indices of lipid peroxidation in vivo. J Biol Chem 274 (1999) 24441
13. Crankshaw D. Effects of the isoprostane, 8-epi-prostaglandin F2 alpha, on the contractility of the human myometrium in vitro. Eur J Pharmacol 285 (1995) 151
14. 2α in some isolated smooth muscle preparations. Br J Pharmacol 130 (2000) 1903
15. 2. Am J Physiol 272 (1997) F477
16. Cracowski J.L., Devillier P., Durand T., Stanke-Labesque F., and Bessard G. Vascular biology of the isoprostanes. J Vase Res 38 (2001) 93
17. Morrow J.D. The isoprostanes-unique products of arachidonate peroxidation: their role as mediators of oxidant stress. Curr Pharm Des 12 (2006) 895
18. Pratico D., Iuliano L., Mauriello A., et al. Localization of distinct F2-isoprostanes in human atherosclerotic lesions. J Clin Invest 100 (1997) 2028
19. Pratico D., Tangirala R.K., Rader D.J., Rokach J., and FitzGerald G.A. Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice. Nat Med 4 (1998) 1189
20. Mallat Z., Philip I., Lebret M., Chatel D., Maclouf J., and Tedgui A. Elevated levels of 8-iso-prostaglandin F2alpha in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. Circulation 97 (1998) 1536
21. Delanty N., Reilly M.P., Pratico D., et al. 8-epi PGF2 alpha generation during coronary reperfusion. A potential quantitative marker of oxidant stress in vivo. Circulation 95 (1997) 2492
22. Antczak A., Montuschi P., Kharitonov S., Gorski P., and Barnes P.J. Increased exhaled cysteinyl-leukotrienes and 8-isoprostane in aspirin-induced asthma. Am J Respir Crit Care Med 166 (2002) 301
23. Dworski R., Murray J.J., Roberts L.J., et al. Allergen-induced synthesis of F(2)-isoprostanes in atopic asthmatics. Evidence for oxidant stress. Am J Respir Crit Care Med 160 (1999) 1947
24. Davi G., Falco A., and Patrono C. Determinants of F2-isoprostane biosynthesis and inhibition in man. Chem Phys Lipids 128 (2004) 149
25. Friedel H.A., and Buckley M.M.T. Torasemide. A review of its pharmacological and therapeutic potential. Drugs 41 (1991) 81
26. Dogne J.M., Wouters J., Rolin S., et al. Design, synthesis and biological evaluation of a sulfonylcyanoguanidine as thromboxane A2 receptor antagonist and thromboxane synthase inhibitor. J Pharm Pharmacol 53 (2001) 669
27. Nuhrich A., Varache-Lèmbege M., Lacan F., and Devaux G. Use of infrared spectroscopy in monitoring a new method for the preparation of sulotroban, an antithrombotic drug. J Chem Educ 319 (1996) 689
28. Masereel B., Damas J., Fontaine J., et al. Thromboxane A2 receptor antagonism in man and rat by a sulphonylcyanoguanidine (BM-144) and a sulphonylurea (BM-500). J Pharm Pharmacol 51 (1999) 695
29. Dogne J.M., de Leval X., Neven P., et al. Effects of a novel non-carboxylic thromboxane A2 receptor antagonist (BM-531) derived from torasemide on platelet function. Prostaglandins Leukot Essent Fatty Acids 62 (2000) 311
30. Dogne J.M., de Leval X., Kolh P., et al. Pharmacological evaluation of the novel thromboxane modulator BM-567 (I/II). Effects of BM-567 on platelet function. Prostaglandins Leukot Essent Fatty Acids 68 (2003) 49
31. Born G.V., and Cross M.J. The aggregation of blood platelets. J Physiol 168 (1963) 178
32. Loi C., Chardigny J.M., Berdeaux O., et al. Effects of three trans isomers of eicosapentaenoic acid on rat platelet aggregation and arachidonic acid metabolism. Thromb Haemost 80 (1998) 656
33. Pratico D., Smyth E.M., Violi F., and FitzGerald G.A. Local amplification of platelet function by 8-Epi prostaglandin F2alpha is not mediated by thromboxane receptor isoforms. J Biol Chem 271 (1996) 14916
34. Halushka P.V. Thromboxane A(2) receptors: where have you gone?. Prostaglandins Other Lipid Mediat 60 (2000) 175
35. Cayatte A.J., Du Y., Oliver-Krasinski J., Lavielle G., Verbeuren T.J., and Cohen R.A. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler Thromb Vase Biol 20 (2000) 1724
36. Balsano F., and Violi F. Effect of picotamide on the clinical progression of peripheral vascular disease. A double-blind placebo-controlled study. The ADEP Group. Circulation 87 (1993) 1563
37. Pratico D., Tillmann C., Zhang Z.B., Li H., and FitzGerald G.A. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc Natl Acad Sci USA 98 (2001) 3358
38. Rolin S., Dogne J.M., Michaux C., Delarge J., and Masereel B. Activity of a novel dual thromboxane A(2)receptor antagonist and thromboxane synthase inhibitor (BM-573) on platelet function and isolated smooth muscles. Prostaglandins Leukot Essent Fatty Acids 65 (2001) 67
39. Rolin S., Petein M., Tchana-Sato V., et al. BM-573, a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, prevents pig myocardial infarction induced by coronary thrombosis. J Pharmacol Exp Ther 306 (2003) 59
40. Ogletree M.L., and Allen G.T. Interspecies differences in thromboxane receptors: studies with thromboxane receptor antagonists in rat and guinea pig smooth muscles. J Pharmacol Exp Ther 260 (1992) 789
41. Delaey C., and Van de Voorde J. Heterogeneity of the inhibitory influence of sulfonylureas on prostanoid-induced smooth muscle contraction. Eur J Pharmacol 325 (1997) 41
42. Kemp B.K., and McPherson G.A. Interspecies differences in thromboxane A2 receptors are distinguished by glibenclamide. Eur J Pharmacol 354 (1998) 173
43. Kinsella B.T., O'Mahony D.J., and Fitzgerald G.A. The human thromboxane A2 receptor alpha isoform (TP alpha) functionally couples to the G proteins Gq and G11 in vivo and is activated by the isoprostane 8-epi prostaglandin F2 alpha. J Pharmacol Exp Ther 281 (1997) 957